Raltegravir (RAL), an HIV integrase inhibitor, may uncommonly induce an increase of serum creatine kinase (CK) both in naïve and antiretroviral (ARV)-experienced HIV-positive patients. We report the case of severe rhabdomyolysis requiring hospitalization in an ARV-experienced HIV/hepatitis C co-infected patient treated with a RAL-containing drug regimen. Factors favouring a severe clinical occurrence of RAL-induced rhabdomyolysis from cases reported in literature are described.
SteigbigelRT, CooperDA, KumarPN, Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med2008;359:339–54
2.
LennoxJL, DeJesusE, LazzarinA, Safety and efficacy of raltegravir based versus efavirenz based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double blind randomized controlled trial. Lancet2009;374:796–806
3.
ConnellyS. Raltegravir NDA 22-145. U.S. Food and Drug Administration Division of Antiviral Products Antiviral Drugs Advisory Committee Meeting; September 5, 2007. See http://www.fda.gov/OHRMS/DOCKETS/AC/07/slides/2007-4314s1-06-connelly.ppt #256,1, Raltegravir (last accessed 12 November 2010)
4.
Isentress. Whitehouse Station. New Jersey: Merck & Co Inc, 2007
5.
ZembowerTR, GerzenshteinL, ColemanK, PalellaFJJr. Severe rhabdomyolysis associated with raltegravir use. AIDS2008;22:1382–4
6.
DoriL, BuonuominiAR, ViscioneM, SarmatiL, AndreoniM. A case of rhabdomyolysis associated with raltegravir use. AIDS2010;24:473–5
7.
MasiáM, EnríquezR, SirventA, GutiérrezF. Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution. J Infect2010;61:189–90
8.
Shere-WolfeKD, VerleyJR. Marked elevation of creatine phosphokinase level in a patient receiving tenofovir. Clin Infect Dis2002;35:1137
9.
PeraultMC, Ladouch-BuresL, DejeanC, Rhabdomyolysis related to ingestion of pravastatin. Therapie1993;48:487
10.
WenningLA, PetryAS, KostJT, Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin Pharmacol Ther2009;85:623–7
